The Chemours Company
NYSE:CCChemicals - Specialty
-$0.27 today
- Market cap
- $1.82B
- Beta
- 1.39
- P/E (TTM)
- -8.0
- EPS (TTM)
- -$2.73
- Dividend yield
- 1.61%
Volume 2.86M
Average 2.80M
CC Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
The Chemours CompanyNYSE: CC
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation growth accelerates
Q2 FY2026 stock-based compensation of $14M rose 100.0% year over year, ahead of the +30.0% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 100.0% from the prior quarter. Over 3 fiscal years it compounded at -8.0% a year.
Context
- Stock-based compensation amounted to 0.4% of revenue in FY2025, up 0.1 pp from a year earlier.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +100.0% holds above the trailing-twelve-month pace of +30.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 21M USD
- Year-over-year change
- +40.0%
- 4-year CAGR
- -11.3%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 21M | +40.0% |
| FY2024 | 2024-12-31 | 15M | -21.1% |
| FY2023 | 2023-12-31 | 19M | -29.6% |
| FY2022 | 2022-12-31 | 27M | -20.6% |
| FY2021 | 2021-12-31 | 34M | — |
Stock-Based Compensation vs competitors
How CC compares with its peers on the latest reported figures
- CC's LTM Jun 2026 stock-based compensation of $26M is the 7th largest of the 19 companies compared; the peer median is $18.84M.
- Its year-over-year change of +30.0% is the 6th highest of 19, against a peer median of -1.8%.
- Stock-based compensation amounts to 0.4% of revenue for CC, versus a peer median of 0.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $105M | -38.2% | +7.5% | 0.3% | |
| LTM Jun 2026 | $88M | +3.5% | +21.6% | 0.9% | |
| LTM Sep 2026 | $61.5M | +222.0% | — | 1.8% | |
| LTM Jun 2026 | $49.4M | -39.2% | -5.6% | 0.4% | |
| LTM Jun 2026 | $37M | -35.1% | +10.6% | 0.2% | |
| LTM Sep 2026 | $31M | -22.5% | +4.4% | 0.3% | |
| LTM Jun 2026 | $26M | +30.0% | -8.0% | 0.4% | |
| LTM Sep 2026 | $25M | -66.7% | +9.1% | 0.1% | |
| LTM Sep 2026 | $22.51M | +53.4% | — | 1.5% | |
| LTM Jun 2026 | $21M | +5.0% | +4.0% | 0.4% | |
| LTM Jun 2026 | $16.69M | +41.3% | -4.7% | 1.0% | |
| LTM Jun 2026 | $15M | +7.1% | -8.0% | 0.8% | |
| LTM Sep 2026 | $13.76M | +5.9% | +5.3% | 0.7% | |
| LTM Jun 2026 | $13M | -7.1% | +1.4% | 0.4% | |
| LTM Aug 2026 | $12.58M | -43.9% | — | 0.4% | |
| LTM Mar 2026 | $11.14M | -17.1% | -22.1% | 1.4% | |
| LTM Jun 2026 | $10.54M | +113.2% | +4.4% | 1.4% | |
| LTM Mar 2026 | $782K | +38.9% | +179.8% | 0.7% | |
| LTM Mar 2026 | $0 | -100.0% | +20.9% | 0.0% | |
| Peer median (excluding CC) | $18.84M | -1.8% | +4.4% | 0.5% | |
Competitors are the stored peer set for CC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 608M | 578M | (238M) | 86M | (386M) |
| Depreciation & Amortization | 317M | 291M | 307M | 301M | 340M |
| Deferred Income Tax | (77M) | 20M | (158M) | (27M) | 64M |
| Stock-Based Compensation | 34M | 27M | 19M | 15M | 21M |
| Change in Working Capital | 21M | (103M) | 620M | (1.05B) | 178M |
| Accounts Receivables | (225M) | 91M | 0 | (152M) | 106M |
| Inventory | (210M) | (294M) | 58M | (146M) | (106M) |
| Accounts Payables | 281M | 105M | (72M) | (9M) | (165M) |
| Other Working Capital | 175M | (5M) | 634M | (745M) | 343M |
| Other Non-Cash Items | (89M) | (58M) | 6M | 44M | 47M |
| Operating Cash Flow | 814M | 755M | 556M | (633M) | 264M |
| Capital Expenditures | (277M) | (307M) | (370M) | (360M) | (213M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 7M |
| Purchases of Investments | (12M) | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 509M | 23M | 141M | 7M | 0 |
| Investing Cash Flow | 220M | (284M) | (229M) | (353M) | (206M) |
| Debt Repayment | (208M) | (80M) | 393M | 95M | (61M) |
| Common Stock Issued | 0 | 0 | 0 | 9M | 0 |
| Common Stock Repurchased | (173M) | (495M) | (69M) | 0 | (1M) |
| Dividends Paid | (164M) | (154M) | (149M) | (148M) | (78M) |
| Other Financing Activities | (9M) | 43M | 16M | 8M | 14M |
| Financing Cash Flow | (554M) | (686M) | 172M | (36M) | (126M) |
| Effect of Forex Changes | (34M) | (32M) | 4M | (22M) | 27M |
| Net Change in Cash | 446M | (247M) | 503M | (1.04B) | (41M) |
| Free Cash Flow | 537M | 448M | 186M | (993M) | 51M |
The Chemours Company
NYSE:CC
Intrinsic Alpha fair value
Locked
Current Price
$12.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.